| Characteristics at Enrollment in HIV Care . | Pre-ART CD4 Testing,a n (% of Total) . | Viral Load Monitoring at 6 Months After ART Initiation,b n (% of Total) . |
|---|---|---|
| Patients | 547 837 | 492 980 |
| Sites | 225 | 224 |
| Countries | 26 | 26 |
| Region | ||
| Asia-Pacific | 7483 (1.4%) | 7076 (1.4%) |
| Central Africa | 31 936 (5.8%) | 31 598 (6.4%) |
| East Africa | 185 469 (33.9%) | 168 495 (34.2%) |
| North America | 25 465 (4.7%) | 24 307 (4.9%) |
| Southern Africa | 282 810 (51.6%) | 248 607 (50.4%) |
| West Africa | 14 674 (2.7%) | 12 897 (2.6%) |
| Country income level | ||
| Low/lower-middle income | 327 750 (59.8%) | 292 380 (59.3%) |
| High/upper-middle income | 220 087 (40.2%) | 200 600 (40.7%) |
| Sex | ||
| Male | 203 359 (37.1%) | 181 545 (36.8%) |
| Female | 344 478 (62.9%) | 311 435 (63.2%) |
| Age at enrollment, years | ||
| Median (IQR) | 33.7 (26.7–41.7) | 33.7 (26.8–41.7) |
| Age group at enrollment | ||
| Adults (>19 years) | 494 661 (90.3%) | 445 893 (90.5%) |
| Adolescents (10–19 years) | 21 336 (3.9%) | 17 992 (3.7%) |
| Children (<10 years) | 31 840 (5.8%) | 29 095 (5.9%) |
| Period of enrollment | ||
| Before Treat-All introduction | 456 466 (83.3%) | 424 671 (86.1%) |
| After Treat-All introduction | 91 371 (16.7%) | 68 309 (13.9%) |
| Characteristics at Enrollment in HIV Care . | Pre-ART CD4 Testing,a n (% of Total) . | Viral Load Monitoring at 6 Months After ART Initiation,b n (% of Total) . |
|---|---|---|
| Patients | 547 837 | 492 980 |
| Sites | 225 | 224 |
| Countries | 26 | 26 |
| Region | ||
| Asia-Pacific | 7483 (1.4%) | 7076 (1.4%) |
| Central Africa | 31 936 (5.8%) | 31 598 (6.4%) |
| East Africa | 185 469 (33.9%) | 168 495 (34.2%) |
| North America | 25 465 (4.7%) | 24 307 (4.9%) |
| Southern Africa | 282 810 (51.6%) | 248 607 (50.4%) |
| West Africa | 14 674 (2.7%) | 12 897 (2.6%) |
| Country income level | ||
| Low/lower-middle income | 327 750 (59.8%) | 292 380 (59.3%) |
| High/upper-middle income | 220 087 (40.2%) | 200 600 (40.7%) |
| Sex | ||
| Male | 203 359 (37.1%) | 181 545 (36.8%) |
| Female | 344 478 (62.9%) | 311 435 (63.2%) |
| Age at enrollment, years | ||
| Median (IQR) | 33.7 (26.7–41.7) | 33.7 (26.8–41.7) |
| Age group at enrollment | ||
| Adults (>19 years) | 494 661 (90.3%) | 445 893 (90.5%) |
| Adolescents (10–19 years) | 21 336 (3.9%) | 17 992 (3.7%) |
| Children (<10 years) | 31 840 (5.8%) | 29 095 (5.9%) |
| Period of enrollment | ||
| Before Treat-All introduction | 456 466 (83.3%) | 424 671 (86.1%) |
| After Treat-All introduction | 91 371 (16.7%) | 68 309 (13.9%) |
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; IQR, interquartile range.
aART-naive patients enrolling in HIV care 2006–2018, with at least 7 days of potential follow-up time after ART initiation.
bART-naive patients enrolling in HIV care 2006–2018 with at least 9 months (273 days) of potential follow-up time after ART initiation.
| Characteristics at Enrollment in HIV Care . | Pre-ART CD4 Testing,a n (% of Total) . | Viral Load Monitoring at 6 Months After ART Initiation,b n (% of Total) . |
|---|---|---|
| Patients | 547 837 | 492 980 |
| Sites | 225 | 224 |
| Countries | 26 | 26 |
| Region | ||
| Asia-Pacific | 7483 (1.4%) | 7076 (1.4%) |
| Central Africa | 31 936 (5.8%) | 31 598 (6.4%) |
| East Africa | 185 469 (33.9%) | 168 495 (34.2%) |
| North America | 25 465 (4.7%) | 24 307 (4.9%) |
| Southern Africa | 282 810 (51.6%) | 248 607 (50.4%) |
| West Africa | 14 674 (2.7%) | 12 897 (2.6%) |
| Country income level | ||
| Low/lower-middle income | 327 750 (59.8%) | 292 380 (59.3%) |
| High/upper-middle income | 220 087 (40.2%) | 200 600 (40.7%) |
| Sex | ||
| Male | 203 359 (37.1%) | 181 545 (36.8%) |
| Female | 344 478 (62.9%) | 311 435 (63.2%) |
| Age at enrollment, years | ||
| Median (IQR) | 33.7 (26.7–41.7) | 33.7 (26.8–41.7) |
| Age group at enrollment | ||
| Adults (>19 years) | 494 661 (90.3%) | 445 893 (90.5%) |
| Adolescents (10–19 years) | 21 336 (3.9%) | 17 992 (3.7%) |
| Children (<10 years) | 31 840 (5.8%) | 29 095 (5.9%) |
| Period of enrollment | ||
| Before Treat-All introduction | 456 466 (83.3%) | 424 671 (86.1%) |
| After Treat-All introduction | 91 371 (16.7%) | 68 309 (13.9%) |
| Characteristics at Enrollment in HIV Care . | Pre-ART CD4 Testing,a n (% of Total) . | Viral Load Monitoring at 6 Months After ART Initiation,b n (% of Total) . |
|---|---|---|
| Patients | 547 837 | 492 980 |
| Sites | 225 | 224 |
| Countries | 26 | 26 |
| Region | ||
| Asia-Pacific | 7483 (1.4%) | 7076 (1.4%) |
| Central Africa | 31 936 (5.8%) | 31 598 (6.4%) |
| East Africa | 185 469 (33.9%) | 168 495 (34.2%) |
| North America | 25 465 (4.7%) | 24 307 (4.9%) |
| Southern Africa | 282 810 (51.6%) | 248 607 (50.4%) |
| West Africa | 14 674 (2.7%) | 12 897 (2.6%) |
| Country income level | ||
| Low/lower-middle income | 327 750 (59.8%) | 292 380 (59.3%) |
| High/upper-middle income | 220 087 (40.2%) | 200 600 (40.7%) |
| Sex | ||
| Male | 203 359 (37.1%) | 181 545 (36.8%) |
| Female | 344 478 (62.9%) | 311 435 (63.2%) |
| Age at enrollment, years | ||
| Median (IQR) | 33.7 (26.7–41.7) | 33.7 (26.8–41.7) |
| Age group at enrollment | ||
| Adults (>19 years) | 494 661 (90.3%) | 445 893 (90.5%) |
| Adolescents (10–19 years) | 21 336 (3.9%) | 17 992 (3.7%) |
| Children (<10 years) | 31 840 (5.8%) | 29 095 (5.9%) |
| Period of enrollment | ||
| Before Treat-All introduction | 456 466 (83.3%) | 424 671 (86.1%) |
| After Treat-All introduction | 91 371 (16.7%) | 68 309 (13.9%) |
Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus; IQR, interquartile range.
aART-naive patients enrolling in HIV care 2006–2018, with at least 7 days of potential follow-up time after ART initiation.
bART-naive patients enrolling in HIV care 2006–2018 with at least 9 months (273 days) of potential follow-up time after ART initiation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
